Preliminary Fourth Quarter 2025 Financial Results

AI SummaryClose X

CelLBxHealth plc anticipates reporting preliminary fourth quarter and full year 2025 revenues of approximately £0.4 million and £1.4 million respectively, with £0.2 million in sales contracts deferred into Q1 2026. The company ended 2025 with £7.3 million in cash and is implementing cost rationalisation measures, including operational consolidation and headcount reductions, expected to yield £5.9 million in annualised savings. CelLBxHealth has also transitioned its ordinary shares from the OTCQX Market to the Pink Limited Market due to low trading volume. The company is focused on its revised business strategy targeting a £12.6 million risk-weighted sales pipeline for 2026/27.

Disclaimer*

UK 100

Latest directors dealings